Sign in
SuspendedPhase 1/2

Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)

Key facts

Who runs it
Sclnow Biotechnology Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Suspended
Phase
Phase 1/2
People taking part
40 people, planned
Starts
31 Dec 2026
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Allogeneic umbilical cord mesenchymal stem cells
  • Decitabine
Record updated
23 April 2026
Why it stopped
Others

Who can take part

Age
60 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • MDS patients with international prostate symptom score is moderate or severe symptoms

Who cannot take part

  • under other therapy that possibly influence MSC security or efficacy
  • bad physical condition (Karmofsky < 60%)
  • HIV or other serious disease infection
  • Donor: HIV, active hepatitis B/C infection, Syphilitic antibody positive
  • Donor/ participants: alcoholism, drug addicted, mental disease
  • with other organ function abnormal: acute hepatitis B, ejection fraction < 40%, serum bilirubin > 3mg/dl, liver function tests abnormal, central nervous system disease, mental disease
  • with serious renal function impaired
  • without signing informed consent form

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purposes of the study is to determine the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating Myelodysplastic Syndrome patients.

The 2 groups in the trial

  • Experimental groupTreatment being tested

    Basic medication: Decitabine; Allogeneic umbilical cord mesenchymal stem cells.

    Treatment: Allogeneic umbilical cord mesenchymal stem cells and Decitabine

  • Control groupPlacebo, for comparison

    Basic medication: Decitabine; placebo: saline.

    Treatment: Decitabine

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)
Record updated
23 April 2026